Radioprotective effects of WR-2721, Broncho-Vaxom® and their combinations: Survival, myelopoietic restoration and induction of colony-stimulating activity in mice

Fedoročko, Peter; Brezáni, P; Macková, N

doi:10.1016/0192-0561(94)90074-4

Cited by 10 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Broncho-Vaxom, a bacterial lysate, has been investigated in combination with amifostine and shown to potentiate its efficacy as radioprotector as well as radiomitigator when amifostine was administered as a radioprotector [126,127]. When both the agents were administered prior to irradiation, the DRF values in mouse survival study have been reported as 1.92, 1.17, and 2.07 for amifostine, Broncho-Vaxom, and amifostine plus Broncho-Vaxom, respectively [126].…”

Section: Combination Of Amifostine With Other Agentsmentioning

confidence: 99%

The efficacy and safety of amifostine for the acute radiation syndrome

Singh

Seed²

2019

Expert Opinion on Drug Safety

109

View full text Add to dashboard Cite

Introduction: A radiation countermeasure that can be used prior to radiation exposure to protect the population from the harmful effects of radiation exposure remains a major unmet medical need and is recognized as an important area for research. Despite substantial advances in the research and development for finding nontoxic, safe, and effective prophylactic countermeasures for the acute radiation syndrome (ARS), no such agent has been approved by the United States Food and Drug Administration (FDA). Area covered: Despite the progress made to improve the effectiveness of amifostine as a radioprotector for ARS, none of the strategies have resolved the issue of its toxicity/side effects. Thus, the FDA has approved amifostine for limited clinical indications, but not for non-clinical uses. This article reviews recent strategies and progress that have been made to move forward this potentially useful countermeasure for ARS. Expert opinion: Although the recent investigations have been promising for fielding safe and effective radiation countermeasures, additional work is needed to improve and advance drug design and delivery strategies to get FDA approval for broadened, non-clinical use of amifostine during a radiological/nuclear scenario. ARTICLE HISTORY

show abstract

Section: Combination Of Amifostine With Other Agentsmentioning

confidence: 99%

The efficacy and safety of amifostine for the acute radiation syndrome

Singh

Seed²

2019

Expert Opinion on Drug Safety

109

View full text Add to dashboard Cite

show abstract

“…Subsequent studies have revealed positive hematological effects of Broncho-Vaxom ® in sublethally irradiated mice [ 56 , 57 , 58 ]. Broncho-Vaxom ® has been also tested with success in its combined administration with the chemical radioprotector WR-2721 (amifostine) [ 59 , 60 ]. Broncho-Vaxom ® has been found to act radioprotectively when administered pre-irradiation [ 55 , 56 , 57 , 58 , 59 , 60 ], as well as a radiomitigator following its post-irradiation administration [ 60 ].…”

Section: Immunomodulatorsmentioning

confidence: 99%

“…Broncho-Vaxom ® has been also tested with success in its combined administration with the chemical radioprotector WR-2721 (amifostine) [ 59 , 60 ]. Broncho-Vaxom ® has been found to act radioprotectively when administered pre-irradiation [ 55 , 56 , 57 , 58 , 59 , 60 ], as well as a radiomitigator following its post-irradiation administration [ 60 ]. In a later study, Broncho-Vaxom ® has been administered to rats in repeated injections comprising one pre-irradiation dose and repeated post-irradiation doses in the course of a three-week period of fractionated irradiation.…”

Section: Immunomodulatorsmentioning

confidence: 99%

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Höfer

Hoferová

Falk

2017

IJMS

View full text Add to dashboard Cite

In recent times, cytokines and hematopoietic growth factors have been at the center of attention for many researchers trying to establish pharmacological therapeutic procedures for the treatment of radiation accident victims. Two granulocyte colony-stimulating factor-based radiation countermeasures have been approved for the treatment of the hematopoietic acute radiation syndrome. However, at the same time, many different substances with varying effects have been tested in animal studies as potential radioprotectors and mitigators of radiation damage. A wide spectrum of these substances has been studied, comprising various immunomodulators, prostaglandins, inhibitors of prostaglandin synthesis, agonists of adenosine cell receptors, herbal extracts, flavonoids, vitamins, and others. These agents are often effective, relatively non-toxic, and cheap. This review summarizes the results of animal experiments, which show the potential for some of these untraditional or new radiation countermeasures to become a part of therapeutic procedures applicable in patients with the acute radiation syndrome. The authors consider β-glucan, 5-AED (5-androstenediol), meloxicam, γ-tocotrienol, genistein, IB-MECA (N6-(3-iodobezyl)adenosine-5’-N-methyluronamide), Ex-RAD (4-carboxystyryl-4-chlorobenzylsulfone), and entolimod the most promising agents, with regards to their contingent use in clinical practice.

show abstract

“…For details on hematologic and radioprotective efficacy of β-glucan, see [ 27 ]. Broncho-Vaxom, a bacterial lysate, has been shown to potentiate in both protective and therapeutic administration settings the radioprotective effects of pre-irradiation amifostine [ 28 , 29 ]. The values of DRF in a survival study have been reported to be 1.92, 1.17, and 2.07 for amifostine alone, Broncho-Vaxom alone, and amifostine + Broncho-Vaxom, respectively, if both the drugs were applied pre-irradiation [ 29 ].…”

Section: Combinations Including Amifostine (Wr-2721)mentioning

confidence: 99%

“…Broncho-Vaxom, a bacterial lysate, has been shown to potentiate in both protective and therapeutic administration settings the radioprotective effects of pre-irradiation amifostine [ 28 , 29 ]. The values of DRF in a survival study have been reported to be 1.92, 1.17, and 2.07 for amifostine alone, Broncho-Vaxom alone, and amifostine + Broncho-Vaxom, respectively, if both the drugs were applied pre-irradiation [ 29 ]. Recent studies on immunomodulators as components of drug combinations tested for their potential radioprotection/radiomitigation comprise polysaccharide from Sipunculus nudus and peptidoglycan.…”

Section: Combinations Including Amifostine (Wr-2721)mentioning

confidence: 99%

Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome—A Concise Review

et al. 2017

View full text Add to dashboard Cite

The goal of combined pharmacological approaches in the treatment of the acute radiation syndrome (ARS) is to obtain an effective therapy producing a minimum of undesirable side effects. This review summarizes important data from studies evaluating the efficacy of combining radioprotective agents developed for administration prior to irradiation and therapeutic agents administered in a post-irradiation treatment regimen. Many of the evaluated results show additivity, or even synergism, of the combined treatments in comparison with the effects of the individual component administrations. It can be deduced from these findings that the research in which combined treatments with radioprotectors/radiomitigators are explored, tested, and evaluated is well-founded. The requirement for studies highly emphasizing the need to minimize undesirable side effects of the radioprotective/radiomitigating therapies is stressed.

show abstract

Radioprotective effects of WR-2721, Broncho-Vaxom® and their combinations: Survival, myelopoietic restoration and induction of colony-stimulating activity in mice

Cited by 10 publications

References 23 publications

The efficacy and safety of amifostine for the acute radiation syndrome

The efficacy and safety of amifostine for the acute radiation syndrome

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome—A Concise Review

Contact Info

Product

Resources

About